Cancer therapy using oligonucleotide-based STAT3 inhibitors: Will they deliver?

Therapeutic Delivery

Volumn 5, Issue 3, 2014, Pages 239-242

  Kortylewski, Marcin ^a   Nechaev, Sergey ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

antisense oligonucleotides; aptamer; cancer immunotherapy; decoy; siRNA; STAT3; TLR9

Indexed keywords

ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; APTAMER; JANUS KINASE INHIBITOR; OLIGODEOXYNUCLEOTIDE; PROTEIN INHIBITOR; SMALL INTERFERING RNA; STAT1 PROTEIN; STAT3 INHIBITOR; STAT3 PROTEIN; TOLL LIKE RECEPTOR 9; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; ANTISENSE THERAPY; B CELL LYMPHOMA; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER RADIOTHERAPY; CANCER THERAPY; CELL SURVIVAL; CHEMICAL MODIFICATION; CROSS PRESENTATION; DRUG DEGRADATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; GENE SILENCING; GENE TARGETING; HEAD AND NECK CANCER; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOSURVEILLANCE; IN VITRO STUDY; LIVER CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; TECHNOLOGY;

ANIMALS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC THERAPY; HUMANS; IMMUNOTHERAPY; NEOPLASMS; OLIGONUCLEOTIDES; OLIGONUCLEOTIDES, ANTISENSE; RNA INTERFERENCE; RNA, SMALL INTERFERING; STAT3 TRANSCRIPTION FACTOR; TREATMENT OUTCOME;

EID: 84896777317     PISSN: 20415990     EISSN: 20416008     Source Type: Journal    
DOI: 10.4155/tde.13.152     Document Type: Review

References (21)

1. Darnell JE Jr. Transcription factors as targets for cancer therapy. Nat. Rev. Cancer 2(10), 740-749 (2002).
2. Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat. Rev. Cancer 9(11), 798-809 (2009).
3. Kontzias A, Kotlyar A, Laurence A, Changelian P, O'Shea JJ. Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease. Curr. Opin. Pharmacol. 12(4), 464-470 (2012).
4. Sen M, Thomas SM, Kim S et al. First-inhuman trial of a STAT3 decoy oligonucleotide in head and neck tumors: implications for cancer therapy. Cancer Discov. 2(8), 694-705 (2012).
5. Kole R, Krainer AR, Altman S. RNA therapeutics: beyond RNA interference and antisense oligonucleotides. Nat. Rev. Drug Discov. 11(2), 125-140 (2012).
6. Burel SA, Han SR, Lee HS et al. Preclinical evaluation of the toxicological effects of a novel constrained ethyl modified antisense compound targeting signal transducer and activator of transcription 3 in mice and cynomolgus monkeys. Nucleic Acid Ther. 23(3), 213-227 (2013).
7. ClinicalTrials Database. www.clinicaltrials.gov
8. Zammarchi F, De Stanchina E, Bournazou E et al. Antitumorigenic potential of STAT3 alternative splicing modulation. Proc. Natl Acad. Sci. USA 108(43), 17779-17784 (2011).
9. Rettig GR, Behlke MA. Progress toward in vivo use of siRNAs-II. Mol. Ther. 20(3), 483-512 (2012).
10. Peschansky VJ, Liang Z, Wahlestedt C. RNAi joins the 'singles club'. Mol. Ther. 20 (11), 2010-2011 (2012).
11. Thiel K W, Giangrande Ph. Intracellular delivery of RNA-based therapeutics using aptamers. Ther. Deliv. 1(6), 849-861 (2010).
12. Ma Y, Kowolik CM, Swiderski PM et al. Humanized Lewis-Y specific antibody based delivery of STAT3 siRNA. ACS Chem. Biol. 6(9), 962-970 (2011).
13. Zhou J, Bobbin ML, Burnett JC, Rossi JJ. Current progress of RNA aptamer-based therapeutics. Front. Genet. 3, 234 (2012).
14. Latz E, Schoenemeyer A, Visintin A et al. TLR9 signals after translocating from the ER to CpG DNA in the lysosome. Nat. Immunol. 5(2), 190-198 (2004).
15. Nechaev S, Gao C, Moreira D et al. Intracellular processing of immunostimulatory CpG-siRNA: Toll-like receptor 9 facilitates siRNA dicing and endosomal escape. J. Control. Release 170, 307-315 (2013).
16. Kortylewski M, Swiderski P, Herrmann A et al. In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses. Nat. Biotechnol. 27(10), 925-932 (2009).
17. Zhang Q, Hossain DM, Nechaev S et al. TLR9-mediated siRNA delivery for targeting of normal and malignant human hematopoietic cells in vivo. Blood 121(8), 1304-1315 (2013).
18. Hossain DM, Dos Santos C, Zhang Q et al. Leukemia cell-targeted STAT3 silencing and TLR9-triggering generate systemic antitumor immunity. Blood 123(1) 15-25, (2013).
19. Mcnamara JO 2nd, Andrechek ER, Wang Y et al. Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nat. Biotechnol. 24(8), 1005-1015 (2006).
20. Zhou J, Tiemann K, Chomchan P et al. Dual functional BAFF receptor aptamers inhibit ligand-induced proliferation and deliver siRNAs to NHL cells. Nucleic Acids Res. 41(7), 4266-4283 (2013).
21. Gao C, Kozlowska A, Nechaev S et al. TLR9 signaling in the tumor microenvironment initiates cancer recurrence after radiation therapy. Cancer Res. 73(24), 7211-7221 (2013).